Status:
COMPLETED
Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Lead Sponsor:
University Hospital Tuebingen
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
Primary Gastric Diffuse-Large B-Cell Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The optimal treatment of primary gastric diffuse large B-cell lymphoma (PG-DLBCL) has not yet been defined. In most circumstances, a stomach-conserving approach is favored, but the role of radiotherap...
Detailed Description
see above
Eligibility Criteria
Inclusion
- Age \> 18 years
- Histologically confirmed primary gastric CD20+ DLBCL
- Written informed consent
- ECOG 0-2
Exclusion
- Secondary aggressive Non-Hodgkin's lymphoma involving the gastric area
- HIV positive patients
- Severe organ dysfunction
- Life expectancy of less than 3 months
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00204659
Start Date
March 1 2003
End Date
September 1 2008
Last Update
October 20 2008
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Zentralklinikum Augsburg
Augsburg, Germany, 86156
2
University of Giessen
Giessen, Germany, 35392
3
Klinikum Reutlingen
Reutlingen, Germany
4
University of Tubingen
Tübingen, Germany, 72076